Journal: Cell Metabolism

Article Title: Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry

doi: 10.1016/j.cmet.2022.01.008

Figure Lengend Snippet:

Article Snippet: Entinostat , MedChenExpress , Cat. HY-12163.

Techniques: Virus, Recombinant, Enzyme-linked Immunosorbent Assay, RNA Extraction, Reverse Transcription, SYBR Green Assay, Activity Assay, Cholesterol Assay, Software

Journal: Neurotoxicity research

Article Title: The MT1G Gene in LUHMES Neurons Is a Sensitive Biomarker of Neurotoxicity

doi: 10.1007/s12640-020-00272-3

Figure Lengend Snippet: Chemicals used and abbreviations

Article Snippet: Chemicals included Ferbam from TCI America, Portland, OR; ML385 and MS275 from Toris Biosciences, Minneapolis, MN; APTO235 (MedChemExpress, Princeton, NJ); and sankel (Muse Chem, Fairfield, NJ).

Techniques:

Journal: Neurotoxicity research

Article Title: The MT1G Gene in LUHMES Neurons Is a Sensitive Biomarker of Neurotoxicity

doi: 10.1007/s12640-020-00272-3

Figure Lengend Snippet: RNA sequencing responses of LUHMES neurons to neurotoxicants. dLUHMES neurons were treated with parkinsonian toxicants 6HD, 6-hydroxydopamine 1 μM; MPP, 1-methyl-4-phenylpyridinium 5 μM, ROT, rotenone 1 μM; and additional neurotoxicants PQ 5 μM, ziram (ZIR) 2 μM, MHG 0.5 μM, and possible neurotoxicant MS275 5 μM (Vashishta and Hetman 2014). a Heatmap shows genes as rows and chemical treatments as columns. Colors indicate increased (red) or decreased (green) mRNA relative to vehicle control with color saturation at 32-fold. No cytotoxicity was observed after 24 h at these concentrations. b Bar graph shows mRNA reads counted per 100 million normalized mRNA transcripts for three metallothionein genes. Among 83 million mRNA reads for three replicate vehicle-treated samples, MT1G, MT1E, and MT2A reads numbered 2, 8, and 42 reads, respectively. ***Ziram-treated dLUHMES neurons yielded 53,000, 31,000 and 31,000 transcripts per 100 million for MT1G, MT1E, and MT2A, respectively. c Dot plot comparing RNA-Seq and qRT-PCR quantitation of responses by six biomarker genes using the samples from “a” above

Article Snippet: Chemicals included Ferbam from TCI America, Portland, OR; ML385 and MS275 from Toris Biosciences, Minneapolis, MN; APTO235 (MedChemExpress, Princeton, NJ); and sankel (Muse Chem, Fairfield, NJ).

Techniques: RNA Sequencing, Control, Quantitative RT-PCR, Quantitation Assay, Biomarker Discovery

Journal: Neurotoxicity research

Article Title: The MT1G Gene in LUHMES Neurons Is a Sensitive Biomarker of Neurotoxicity

doi: 10.1007/s12640-020-00272-3

Figure Lengend Snippet: Transcriptional responses of three biomarker genes to 15 toxicants in six cell lines. The six cell lines indicated at left were treated with vehicle or one of 15 toxicants. Transcriptional responses by DDIT3, MT1G, PDK4, and GAPDH were quantified by qRT-PCR at 6 h, and cell viability was assessed at 24 h as intracellular [ATP]. Below the four genes for each cell line is a row of cells that indicate cell viability. White indicates no detectable loss of viability whereas blue color saturation indicates the % of cell death 24 h post-treatment. Toxicant treatments were HCP, Hexachlorophene 10 μM; CAP, captan 10 μM; 6HD, 6-hydroxydopamine 3 μM; MAP, 4-(methylamino)phenol hemisulfate salt 5 μM; CR2, sodium dichromate 5 μM; CLM, chlorambucil 10 μM; MPP, 1-methyl-4-phenylpyridinium 10 μM; MNC, manganese chloride 10 μM; PQ, paraquat 10 μM; STA, staurosporine 2 μM; ROT, rotenone 3 μM; MS5, MS275 10 μM; TER, terfenadine 10 μM; MHG, methylmercury chloride 2 μM; ZIR, ziram, 6 μM

Article Snippet: Chemicals included Ferbam from TCI America, Portland, OR; ML385 and MS275 from Toris Biosciences, Minneapolis, MN; APTO235 (MedChemExpress, Princeton, NJ); and sankel (Muse Chem, Fairfield, NJ).

Techniques: Biomarker Discovery, Quantitative RT-PCR

Journal: PLoS ONE

Article Title: The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells

doi: 10.1371/journal.pone.0127058

Figure Lengend Snippet: Overview of the patient-derived GSC cultures tested for combination treatment.

Article Snippet: The HDACi tested were SAHA and MS275 (Cayman chemicals, MI, USA), VPA (Sigma-Aldrich, MO, USA), LBH589 (Biovision, CA, USA), and Scriptaid (Santa Cruz Biotechnology, CA, USA).

Techniques: Methylation

Journal: PLoS ONE

Article Title: The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells

doi: 10.1371/journal.pone.0127058

Figure Lengend Snippet: (A-E) The eight patient-derived GSC cultures that were treated according to a simultaneous treatment schedules of HDACi and Delta24-RGD at indicated concentrations and MOIs, respectively. The treatments were added concomitantly to the cells. Results are shown for one dose of drug and one dose of oncolytic virus, for Scriptaid (A), LBH589 (B), SAHA(C), VPA (D) and MS275 (E). Response was defined as a reduction in viability, which was significantly different from both mono-treatments (p<0.05), and is indicated in the graph by the blue bars (responders). If not meeting these criteria, the culture was defined as resistant (red bars). The results are displayed by the mean viability % ± standard deviations of triplicates. *Indicates significance of combination treatment compared to HDACi or Delta24-RGD alone, p<0.05.

Article Snippet: The HDACi tested were SAHA and MS275 (Cayman chemicals, MI, USA), VPA (Sigma-Aldrich, MO, USA), LBH589 (Biovision, CA, USA), and Scriptaid (Santa Cruz Biotechnology, CA, USA).

Techniques: Derivative Assay, Virus